Refine by
Patient Diagnostic Articles & Analysis: Older
141 news found
In July 2021, the company received $153,300 for a $204,400 project to develop a prototype drape to shield medical imaging machines from patient contamination. “As a company founded and headquartered in Ontario, we are committed to helping to improve the health of Ontarians through our on-going development of innovative technology,” said Cameron Piron, President, ...
It is particularly useful in enabling the very young, frail, or patients with a disability to perform respiratory assessments, as no forced maneuver is required. Speaking of the new addition to the Vitalograph family of respiratory diagnostic solutions, Vice President of Global Marketing for Vitalograph, Ross Warner said: “The addition of oscillometry is ...
Vitalograph, a global leader in the development and production of respiratory diagnostic solutions and clinical trial services, has launched the Vitalograph tremoflo® C-100 at this year’s ATS International Conference, taking place in Washington. ...
Instand-NGS4P is a Horizon 2020 funded project that shares BC Platforms vision for improving cancer patients’ diagnostics. This is achieved by developing and providing integrated and standardized workflows for Next Generation Sequencing (NGS) and integrating information from cancer gene testing, pharmacogenetics testing and e-medication, to support medical ...
This research opens a new interesting way to look at the very rare cancer cells in the patient bloodstream. Rarecells Diagnostics (France), a leading liquid biopsy company, is pleased to announce that the University Medical Center of Groningen, The Netherlands, has published research comparing the performance of the ISET technology to the reference ...
The total cost to rapidly identify organisms from positive blood cultures could be at least fifty percent less than what you're paying today for a rapid molecular ID solution," said Jack Phillips, President, and CEO of Accelerate Diagnostics. "When you think of the extreme pressure that labs are under today, the Arc is a fast and inexpensive diagnostic tool which ...
Proprietary microRNA signature (miRisk) may support immunotherapy treatment decisions as a blood-based complementary diagnostic Results published in Journal of Thoracic Oncology Clinical and Research Reports Hummingbird Diagnostics GmbH, a leader in reading blood-based microRNAs for early disease detection and characterization, today announced a publication ...
She brings decades of global experience in clinical research and development, commercialization, patient engagement, and regulatory strategy. Prior to joining Altoida, Dr. ...
The trial demonstrates that using Unyvero HPN panel in hospitalized pneumonia patients for the examination of bronchoalveolar lavage (BAL) in combination with antibiotic stewardship decreases the duration of inappropriate antibiotic therapy of hospitalized patients with pneumonia at risk for Gram-negative bacteria and supports antibiotic de-escalation in 66% of ...
IRVINE, CA, and HERSTAL, BELGIUM – May 19, 2022 – – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial stage precision diagnostics company, announces that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies under its MolDX program, has finalized a foundational Local Coverage Determination ...
Babson Diagnostics, a science-first, health care technology company, and BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the expansion of a strategic partnership to move blood sample collection into new care settings, including enabling patients to collect blood samples at home for ...
“We are excited to work alongside Interpace Diagnostics and Twist Bioscience in providing better solutions in cancer diagnostics for patients and patients’ families,” said Alejandro Tocigl, Miroculus CEO. ...
Blood-based test holds potential for broad applicability for the management of patients with cancer. Hummingbird Diagnostics GmbH, a leader in reading blood-based microRNAs for early disease detection and characterization, today announced the publication of a study in the journal npj Precision Oncology that describes the discovery and validation of miRisk, a ...
Ascelia Pharma today announced and welcomed the results of independent market research showing that 84% of healthcare professionals will likely use Orviglance for magnetic resonance imaging (MRI) in patients with cancer in the liver and reduced kidney function. The independently conducted survey asked 270 healthcare professionals in the US (radiologists, oncologists and ...
One of them is by investing in portable scanners, adopting huge benefits for improved healthcare procedures. What is a portable diagnostic reader? Usually a handheld device, measuring health parameters and helping to diagnose a patient using smart algorithms from a chosen assay. ...
The Phase III pivotal trial is currently enrolling patients in the U.S. Four world-class Canadian clinical sites are currently working through the activation process in order to be ready to begin enrolling patients in the near future. ...
The therapy incorporates a pre-procedural screening assay to identify patients who may be likely responders, a first for a cardiac cell therapy designed to enhance patient selection. ...
Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. ...
The approval indicates the vaccine production is at a high standard which will help to secure timely patient access to vaccines in the Gulf Cooperation Council (GCC) countries and wider Middle Eastern region. ...
Specific Diagnostics today announced formation of its US commercial sales, service, support and marketing teams in anticipation of the launch of the Reveal Rapid AST System for blood infection samples. ...